Effects of dextromethorphan as add-on to sitagliptin on blood glucose and serum insulin concentrations in individuals with type 2 diabetes mellitus: A randomized, placebo-controlled, double-blinded, multiple crossover, single-dose clinical trial.

Effects of dextromethorphan as add-on to sitagliptin on blood glucose and serum insulin concentrations in individuals with type 2 diabetes mellitus: A randomized, placebo-controlled, double-blinded, multiple crossover, single-dose clinical trial. Diabetes Obes Metab. 2015 Sep 12; Authors: Marquard J, Stirban A, Schliess F, Sievers F, Welters A, Otter S, Fischer A, Wnendt S, Meissner T, Heise T, Lammert E Abstract In this clinical trial, we investigated the BG-lowering effects of 30, 60 and 90 mg DXM as well as 100 mg sitagliptin (Sita) alone versus combinations of DXM and Sita during an oral glucose tolerance test (OGTT) in 20 male individuals with T2DM. The combination of 60 mg DXM plus 100 mg Sita showed the strongest effect in the OGTT. It lowered maximum BG concentrations and increased baseline-adjusted area under the curve of serum insulin concentrations in the first 30 minutes of the OGTT (Mean±SD: 240 ± 47 mg/dl and 8.1 ± 6.1 mU/l/h, respectively) to a significantly larger extent than did 100 mg Sita alone (254 ± 50 mg/dl and 5.8 ± 2.5 mU/l/h; p<0.05) and placebo (272 ± 49 mg/dl and 3.9 ± 3.0 mU/l/h; p<0.001). All study drugs were well tolerated, alone and in combination, without serious adverse events or hypoglycemia. Long-term clinical trials are now warranted to investigate the potential of the combination of 30 or 60 mg DXM and DPP-4 inhibitors in the treatment of indi...
Source: Diabetes Metab - Category: Endocrinology Authors: Tags: Diabetes Obes Metab Source Type: research